Opinion|Videos|January 27, 2025
Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
Author(s)Rebecca A. Shatsky, MD, Casey Degen, MD
Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What specific patient characteristics influence your choice between abemaciclib and ribociclib?
- In which scenarios would you preferentially choose abemaciclib over ribociclib? Ribociclib over abemaciclib?
- Could you discuss your approach to toxicity management with adjuvant CDK4/6 inhibitors?
- How do the different safety profiles of abemaciclib and ribociclib impact your patient selection? How do you weigh clinical considerations and comorbidities in your selection considerations?
- What strategies have you found most effective for maintaining dose intensity while managing adverse effects?
- How has real-world experience with adjuvant CDK4/6 inhibitors matched up with clinical trial data?
- What have been your key learnings about patient selection and management?
- How do you handle patients who struggle with adherence or toxicity in the first few months?
Advertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
4
NMA Associates MRD-Negative CR With PFS in Earlier-Line R/R Myeloma
5